| Opportunity ID: | 330003 |
| Opportunity Number: | FOR-FD-20-027 |
| Opportunity Title: | Dermal Physiologically-Based Pharmacokinetic (PBPK) Models Accounting for the Absorption and Evaporation of Vehicle/Co-Solvent Following the Application of Generic Dermatological Products |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Agriculture
Consumer Protection
Food and Nutrition |
| Category Explanation: | |
| CFDA Number(s): | 93.103 |
| Eligible Applicants: | State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses |
| Additional Information on Eligibility: | |
| Agency Code: | HHS-FDA |
| Agency Name: | Department of Health and Human Services
Food and Drug Administration |
| Posted Date: | Nov 23, 2020 |
| Last Updated Date: | Nov 23, 2020 |
| Estimated Synopsis Post Date: | |
| Fiscal Year: | 2021 |
| Award Ceiling: | |
| Award Floor: | |
| Estimated Total Program Funding: | |
| Expected Number of Awards: | |
| Description: | The overall objective of this funding opportunity is to develop an enhanced mechanistic PBPK model for generic dermatological drug products by accounting for the absorption and evaporation of vehicle/co-solvent simultaneously and implementing the effect of these two dynamic processes on the permeation of a drug molecule through skin. The developed model will be utilized to inform decisions on generic dermatological product development, to enhance the understanding of the effect of metamorphosis of dermatological drug products on skin absorption, and to predict the local and systemic exposure of a drug molecule following topical application of dermatological drug products. |
| Version: | 1 |
